Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy

1 Sept 2023

Abstract excerpt

Previous chemotherapy research has focused almost exclusively on apoptosis. Here, a standard frontline drug combination of cytarabine and idarubicin induces distinct features of caspase-independent, poly(ADP-ribose) polymerase 1 (PARP-1)-mediated programmed cell death "parthanatos" in acute myeloid leukemia (AML) cell lines (n = 3/10 tested), peripheral blood mononuclear cells from healthy human donors (n = 10/10...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37683650
DOI: 10.1016/j.xcrm.2023.101191

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapyPMID 37683650Read ↗

Different regulation of PARP1, PARP2, PARP3 and TRPM2 genes expression in acute myeloid leukemia cellsSemantic proximity Read ↗

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategiesSemantic proximity Read ↗

Parthanatos, a messenger of deathSemantic proximity Read ↗

PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.Semantic proximity Read ↗

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndromeSemantic proximity Read ↗

Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case seriesSemantic proximity Read ↗

Different regulation of PARP1, PARP2, PARP3 and TRPM2 genes expression in acute myeloid leukemia cellsSemantic proximity Read ↗

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cellsSemantic proximity Read ↗

PARP-1 Overexpression as an Independent Prognostic Factor in Adult Non-M3 Acute Myeloid Leukemia.Semantic proximity Read ↗

Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: From pathogenesis to therapeutic opportunitiesSemantic proximity Read ↗

Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.Semantic proximity Read ↗

Parthanatos: mitochondrial‐linked mechanisms and therapeutic opportunitiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.